Status: IPO (NASDAQ: SBTX), M&A   Silverback is a clinical-stage biopharmaceutical company leveraging on their proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The platform enables them to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Their research includes the creation of a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.   Silverback was listed on NASDAQ in 2020 and subsequently acquired by ARS Pharmaceuticals (NASDAQ: SPRY) in 2022.   To learn more, please visit: www.ars-pharma.com    

Back to Portfolio